Acute on Chronic Kidney Disease Management

Immediate Nephrotoxin Management

• The American Society of Nephrology recommends discontinuing all potentially nephrotoxic medications immediately, as drugs account for 20% of community-acquired AKI episodes requiring hospitalization and 25% of AKI in critically ill patients 1, 2
• The National Kidney Foundation suggests prioritizing the discontinuation of NSAIDs, especially when combined with diuretics and ACE inhibitors/ARBs, due to the increased risk of AKI 3, 4
• The European Renal Association recommends avoiding non-essential nephrotoxins where less toxic alternatives exist, and discontinuing medications identified as causally related to the acute deterioration through temporal assessment 1, 2, 3
• The American College of Cardiology recommends holding ACE inhibitors and ARBs during the acute phase when GFR is unstable or volume status is not optimized, and restarting only after GFR stabilizes and volume status is optimized 2, 5

Volume Status Optimization

• The International Society of Nephrology recommends assessing and correcting volume depletion or overload immediately, and using aggressive intravenous fluid resuscitation for volume depletion 4
• The National Institute of Diabetes and Digestive and Kidney Diseases suggests monitoring hourly urine output with bladder catheter placement in severe cases 4

Medication Review and Dose Adjustment

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend performing immediate comprehensive medication reconciliation at the transition of care, and adjusting doses based on current GFR using validated eGFR equations 6, 7
• The American Society of Nephrology suggests considering creatinine-cystatin C equations or measured GFR for narrow therapeutic window drugs, and recognizing that AKI impairs hepatic cytochrome P450 activity, affecting drug metabolism beyond renal clearance 1, 2, 6, 7

Laboratory Monitoring Protocol

• The National Kidney Foundation recommends establishing intensive monitoring during the acute phase, including daily eGFR and serum creatinine, and daily to twice daily electrolytes (especially potassium) 4, 5, 6, 7
• The European Renal Association suggests monitoring therapeutic drug levels for medications with narrow therapeutic windows, and obtaining urinalysis and culture if infection is suspected 6, 7, 8

Identify and Treat Underlying Causes

• The American College of Physicians recommends systematically evaluating for reversible causes, including prerenal, intrarenal, and postrenal causes, and obtaining urine studies to differentiate causes 5, 6
• The International Society of Nephrology suggests treating underlying infections promptly, and avoiding delays in essential antibiotics 3, 8

Critical Pitfalls to Avoid

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend never combining multiple nephrotoxins, and avoiding macrolide-statin combinations due to rhabdomyolysis risk from CYP3A4 inhibition 3
• The American Society of Nephrology suggests never failing to document medication restart plans, and educating patients to avoid NSAIDs and new medications without consulting their physician 3, 6, 7

Vancomycin Use in Acute Kidney Injury

Introduction to Vancomycin-Associated AKI

• The European Renal Association acknowledges that treatment of infections necessary for survival should begin immediately and might actually prevent or ameliorate AKI, and notes that vancomycin may be used in life-threatening infections when no less nephrotoxic alternative antibiotic is available 9
• The National Kidney Foundation identifies the combination of NSAIDs, diuretics, and ACE inhibitors/ARBs as particularly high-risk for AKI, with each additional nephrotoxin presenting 53% greater odds of developing AKI 9

Comprehensive Medication Review and Nephrotoxin Management

• The International Society of Nephrology recommends immediate assessment and correction of volume depletion or overload, and the American College of Cardiology suggests holding ACE inhibitors and ARBs during the acute phase when GFR is unstable or volume status is not optimized, while the European Renal Association notes that vancomycin may be used in life-threatening infections when no less nephrotoxic alternative antibiotic is available 9
• Recent data demonstrates that combining 3+ nephrotoxins more than doubles the risk of AKI, with a 53% greater odds of developing AKI for each additional nephrotoxin 9

Infection Severity Assessment and Vancomycin Restart Criteria

• The European Renal Association acknowledges that the infection is life-threatening and requires immediate treatment, and that no less nephrotoxic alternative antibiotic is available, and notes that the temporal assessment confirms vancomycin was causally related to the AKI 9
• The European Renal Association recommends considering vancomycin restart only when the infection is life-threatening and requires immediate treatment, and when no less nephrotoxic alternative antibiotic is available, with a strength of evidence based on clinical guidelines and expert opinion 9

Management of Medications in Acute Kidney Injury

Medication Adjustment and Monitoring

• The decision framework for managing medications in AKI should consider renal versus non-renal excretion, potential for nephrotoxicity, strength of indication for the drug, and availability of suitable alternatives, as recommended by the National Kidney Foundation 10
• Furosemide should not be used to "reverse" established AKI in oliguric patients, as this leads to inappropriate fluid overload without benefit, according to the American Society of Nephrology 11

Management of Nephrotoxic Medications in Acute Kidney Injury

Immediate Discontinuation of High‑Risk Nephrotoxins

• In patients with acute kidney injury (AKI), all non‑essential non‑steroidal anti‑inflammatory drugs (NSAIDs) should be stopped immediately because they induce renal vasoconstriction by inhibiting prostaglandin synthesis, a mechanism essential for maintaining renal perfusion in compromised kidneys. 12
• NSAIDs must remain discontinued throughout both the persistent phase of AKI and the subsequent recovery phase to avoid further renal injury. 12

Conditional Use of Aminoglycosides

• Aminoglycoside antibiotics should be avoided in AKI unless they provide a clear efficacy advantage with no suitable alternative therapy. 12
• When an aminoglycoside is indispensable for a life‑threatening infection, it should be administered with careful dose adjustment and therapeutic drug monitoring to minimize tubular toxicity. 12

Avoidance of Specific Nephrotoxic Agents

• Radiocontrast media should not be administered to patients with AKI unless absolutely essential, as contrast agents cause renal vasoconstriction and direct tubular injury. 12
• High‑dose acyclovir and related antivirals must be avoided in AKI because they precipitate crystals within renal tubules, leading to obstructive AKI. 12

Medication Reintroduction During Recovery

• During the recovery phase of AKI, clinicians should systematically reassess all previously held medications to determine which can be safely re‑introduced, guided by the patient’s improving renal function. 12
• NSAIDs should continue to be avoided until the patient achieves full renal recovery. 12

Ketorolac Contraindication in Acute Kidney Injury

Regulatory and Guideline Contraindications

Contribution of Nephrotoxins to AKI

Clinical Decision Algorithm for AKI

Monitoring and Safety Requirements

Absolute Prohibition Statement

Management of Sacubitril/Valsartan in Acute Kidney Injury

Restarting Therapy After Stabilization

• Resume sacubitril/valsartan at a reduced dose (e.g., 24/26 mg twice daily) once renal function is no longer rising and the patient is euvolemic; then uptitrate only after 2–4 weeks of tolerated therapy. The European Society of Cardiology (based on European Heart Journal data) recommends this cautious re‑initiation and gradual dose escalation. 14

Hyper‑Kalemia Management

• If serum potassium exceeds 5.5 mmol/L, halve the sacubitril/valsartan dose; if it exceeds 6.0 mmol/L, discontinue the drug immediately. This dosing adjustment algorithm is endorsed by the European Society of Cardiology. 14

Monitoring Schedule Post‑Restart

• During weeks 2–4 after re‑initiation, check serum creatinine twice weekly; if stable, maintain the current dose. (European Society of Cardiology) 14
• After 4 weeks of stable renal function and tolerability, consider gradual uptitration toward the target dose. (European Society of Cardiology) 14

Interpretation of Small Creatinine Increases

• A rise in serum creatinine of up to 30 % from baseline after initiating or intensifying renin‑angiotensin system blockade is generally expected and does not constitute true acute kidney injury. This observation is supported by data from the Diabetes Care journal. 15
• In the ACCORD‑BP trial, participants who experienced ≤30 % creatinine elevation with intensive blood‑pressure lowering showed no increase in mortality or progression of kidney disease. (High‑quality randomized trial evidence) 15